go back

Brexucabtagene Autoleucel (Tecartus)

Kansas rates for HCPCS C9073

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $389,045 · 10th–90th $389,045$389,0450%50%100%$389,045Professionalmedian $977,237 · 10th–90th $977,237$977,2370%50%100%$977,237$500.0K$1.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
Medica
Setting
Facility
Modifier
Global
Typical Low
$389,045.14
Median
$389,045.14
Typical High
$389,045.14
Medica
Setting
Professional
Modifier
Global
Typical Low
$977,237.22
Median
$977,237.22
Typical High
$977,237.22